3/25/2013

Ariad Pharmaceuticals' Iclusig, or ponatinib, was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use
as a treatment for chronic, accelerated or blast-phase chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia.

Related Summaries